/GTTX.CN

GTTX.CN Stock - GeneTether Therapeutics Inc.

Q: What is the analyst price target for GTTX.CN?

Analyst price target information is not currently available for GTTX.CN.

Q: What is GTTX.CN's market cap?

Market capitalization information is not currently available for GTTX.CN.

Healthcare|Biotechnology|CNQ

$0.12+0.00%

+$0.00 (+0.00%) • Jan 7

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

High Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

100

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.13

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for GTTX.CN

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2019

FY2020

FY2021

FY2022

FY2023

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta-1.56

52W High$0.12

52W Low$0.12

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2023	FY2022	FY2021	FY2020	FY2019
Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A
Gross Margin	N/A	N/A	N/A	N/A	N/A
Operating Income	$-747,277	$-1,717,234	$-1,636,933	$-71,962	$-86,232
Net Income	$-688,359	$-1,713,270	$-1,637,892	$-73,970	$-86,741
Net Margin	N/A	N/A	N/A	N/A	N/A
EPS	$-0.01	$-0.04	$-0.04	$-0.00	$-0.00

Company Overview

GeneTether Therapeutics Inc., a genetic medicines company, focuses on developing gene editing therapies to enhance the efficiency of genome editing technologies. It is developing gene therapies for the treatment of patients with rare and monogenic kidney and skin diseases. The company was founded in 2018 and is based in Kelowna, Canada.

Visit Website

Earnings History & Surprises

GTTX.CN

Beat Rate

Last 0 quarters

Avg Surprise

+0%

EPS vs Estimate

Beats / Misses

0/0

Last 12 quarters

Latest EPS

$-0.00

Q3 2023

EPS Surprise History

Q1 23

No data

Q2 23

No data

Q3 23

No data

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q3 2023	Sep 30, 2023	—	$-0.00	—	—
Q2 2023	Jun 30, 2023	—	$-0.00	—	—
Q1 2023	Mar 31, 2023	—	$-0.00	—	—

Frequently Asked Questions about GTTX.CN

What is GTTX.CN's current stock price?

GeneTether Therapeutics Inc. (GTTX.CN) is currently trading at $0.12 per share. The stock has moved +0.00% today.

What is the analyst price target for GTTX.CN?

No analyst price targets are currently available for this stock.

What sector is GeneTether Therapeutics Inc. in?

GeneTether Therapeutics Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the CNQ exchange.

What is GTTX.CN's market cap?

GeneTether Therapeutics Inc. has a market capitalization of $0.00 billion, making it a small-cap company.

Does GTTX.CN pay dividends?

No, GeneTether Therapeutics Inc. does not currently pay a dividend to shareholders.